BIOCRYST PHARMACEUTICALS INC (BCRX) › Total AssetsBIOCRYST PHARMACEUTICALS INC (BCRX) — Total AssetsAnnual figures by period end, from SEC filings.2010-12-31: $109.45M2011-12-31: $82.21M2012-12-31: $57.44M2013-12-31: $48.87M2014-12-31: $136.87M2015-12-31: $122.36M2016-12-31: $89.85M2017-12-31: $178.26M2018-12-31: $146.84M2019-12-31: $175.28M2020-12-31: $334.71M2021-12-31: $588.15M2022-12-31: $550.00M2023-12-31: $516.96M2024-12-31: $490.42M2025-12-31: $514.16M$514.16M2010-12-31Total Assets (USD)2025-12-31Period endedTotal AssetsChange YoYSource filing2025-12-31$514.16M+4.8%2026-02-26Balance as of period end2024-12-31$490.42M-5.1%2026-02-26Balance as of period end2023-12-31$516.96M-6.0%2025-02-25Balance as of period end2022-12-31$550.00M-6.5%2024-02-27Balance as of period end2021-12-31$588.15M+75.7%2023-02-27Balance as of period end2020-12-31$334.71M+91.0%2022-02-28Balance as of period end2019-12-31$175.28M+19.4%2021-03-01Balance as of period end2018-12-31$146.84M-17.6%2020-03-13Balance as of period end2017-12-31$178.26M+98.4%2019-03-14Balance as of period end2016-12-31$89.85M-26.6%2018-03-12Balance as of period end2015-12-31$122.36M-10.6%2017-02-27Balance as of period end2014-12-31$136.87M+180.1%2016-02-26Balance as of period end2013-12-31$48.87M-14.9%2015-03-02Balance as of period end2012-12-31$57.44M-30.1%2014-03-10Balance as of period end2011-12-31$82.21M-24.9%2013-03-11Balance as of period end2010-12-31$109.45M—2012-03-06Balance as of period endOther metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)